NEW YORK, NY / ACCESSWIRE / March 8, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
DBV Technologies S.A. (DBVT)
Class Period: February 14, 2018 - December 19, 2018
Lead Plaintiff Deadline: March 18, 2019
Join the action: https://www.zlk.com/pslra-1/dbv-technologies-s-a-loss-form?wire=3
Allegations: DBV Technologies S.A. made materially false and/or misleading statements and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the DBV Technologies S.A. class action contact email@example.com.
Activision Blizzard, Inc. (ATVI)
Class Period: August 2, 2018 - January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
Join the action: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-form?wire=3
Allegations: During the class period, Activision Blizzard, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie's partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies' relationship would foreseeably have a significant negative impact on Activision Blizzard's revenues; and (iii) as a result, Activision Blizzard's public statements were materially false and misleading at all relevant times.
To learn more about the Activision Blizzard, Inc. class action contact firstname.lastname@example.org.
AVEO Pharmaceuticals, Inc. (AVEO)
Class Period: August 4, 2016 - January 31, 2019
Lead Plaintiff Deadline: April 26, 2019
Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?wire=3
Allegations: AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO's public statements were materially false and misleading at all relevant times.
To learn more about the AVEO Pharmaceuticals, Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: